For the quarter ending 2026-03-31, HBIO had -$1,516K decrease in cash & cash equivalents over the period. -$1,088K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss on pension settlement - note 8 | - | 1,233 | 0 | - |
| Loss on extinguishment of debt | - | -130 | - | - |
| Loss on equity securities - note 12 | - | 0 | 0 | 0 |
| Net loss | -3,424 | -2,847 | -1,231 | -52,622 |
| Depreciation | 443 | 456 | 425 | 862 |
| Amortization of intangible assets | 907 | 894 | 899 | 2,409 |
| Goodwill impairment - note 5 | 0 | 0 | 0 | 47,951 |
| Amortization of deferred financing costs | 446 | 624 | 357 | 341 |
| Stock-based compensation | 257 | 459 | 324 | 1,072 |
| Deferred income taxes and other | 85 | 127 | -20 | 573 |
| Accounts receivable | -1,406 | 3,956 | 210 | -3,232 |
| Inventories | 1,540 | -663 | -637 | -1,647 |
| Other assets | 392 | -1,100 | -368 | -53 |
| Accounts payable and other liabilities | 1,181 | 797 | -271 | 1,774 |
| Contract liabilities | 139 | 478 | -234 | -405 |
| Net cash provided by operating activities | -662 | -96 | 1,084 | 5,741 |
| Proceeds from sale of marketable equity securities | - | 0 | 0 | 0 |
| Additions to property, plant and equipment | 426 | 449 | 207 | 602 |
| Capitalized software development costs | 194 | 150 | 141 | 314 |
| Net cash used in investing activities | -620 | -599 | -348 | -916 |
| Borrowing from revolving line of credit | - | 0 | 0 | 0 |
| Borrowing from term loans | - | 40,000 | - | - |
| Repayment of revolving line of credit | - | 12,650 | 0 | 0 |
| Repayment of term debt | 0 | 21,700 | 1,000 | 2,000 |
| Payment of debt issuance costs | 129 | 3,145 | 254 | 433 |
| Proceeds from exercise of stock options and employee stock purchase plan | 150 | 1 | 0 | 46 |
| Taxes paid related to net share settlement of equity awards | 30 | 57 | 24 | 75 |
| Net cash used in financing activities | -9 | 2,449 | -1,278 | -2,462 |
| Effect of exchange rate changes on cash | -225 | 43 | -83 | 971 |
| Increase (decrease) in cash and cash equivalents | -1,516 | 1,797 | -625 | 3,334 |
| Cash and cash equivalents at beginning of period | 8,614 | 6,817 | 4,108 | - |
| Cash and cash equivalents at end of period | 7,098 | 8,614 | 6,817 | - |
HARVARD BIOSCIENCE INC (HBIO)
HARVARD BIOSCIENCE INC (HBIO)